image credit: Unsplash

Catalent to Acquire Bone Therapeutics’ Cell Therapy Mfg. Facility

October 29, 2020

Catalent has signed an agreement with Bone Therapeutics to acquire its cell therapy manufacturing subsidiary, Skeletal Cell Therapy Support SA (SCTS), including all of its assets located in Gosselies, Belgium.

Catalent will purchase the shares of SCTS, currently held by Bone Therapeutics, which owns and operates a purpose-built CGxP facility of approximately 41,000 square-foot, including its related quality control and product development labs, warehouse, grade C and B cleanrooms and equipment as well as land for further development. Catalent will undertake the manufacturing of clinical material for Bone Therapeutics’ drug, ALLOB, an allogeneic osteoblastic cell therapy product, derived from ex vivo cultured bone marrow cells.

Read More on Contract Pharma